Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer’s disease

Vascular endothelial growth factor (VEGF) is associated with the clinical manifestation of Alzheimer’s disease (AD). However, the role of the VEGF gene family in neuroprotection is complex due to the number of biological pathways they regulate. This study explored associations between brain expression of VEGF genes with cognitive performance and AD pathology. Genetic, cognitive, and neuropathology data were acquired from the Religious Orders Study and Rush Memory and Aging Project. Expression of ten VEGF ligand and receptor genes was quantified using RNA sequencing of prefrontal cortex tissue. Global cognitive composite scores were calculated from 17 neuropsychological tests. β-amyloid and tau burden were measured at autopsy. Participants ( n = 531) included individuals with normal cognition ( n = 180), mild cognitive impairment ( n = 148), or AD dementia ( n = 203). Mean age at death was 89 years and 37% were male. Higher prefrontal cortex expression of VEGFB , FLT4 , FLT1 , and PGF was associated with worse cognitive trajectories ( p ≤ 0.01). Increased expression of VEGFB and FLT4 was also associated with lower cognition scores at the last visit before death ( p ≤ 0.01). VEGFB , FLT4 , and FLT1 were upregulated among AD dementia compared with normal cognition participants ( p ≤ 0.03). All four genes associated with cognition related to elevated β-amyloid ( p ≤ 0.01) and/or tau burden ( p ≤ 0.03). VEGF ligand and receptor genes, specifically genes relevant to FLT4 and FLT1 receptor signaling, are associated with cognition, longitudinal cognitive decline, and AD neuropathology. Future work should confirm these observations at the protein level to better understand how changes in VEGF transcription and translation relate to neurodegenerative disease.